Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...
The company said Tuesday that the FDA lifted the hold on an Investigational New Drug Application for a phase 3 clinical trial of nexiguran ziclumeran, or nex-z, for patients with a genetic disease ...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a registrational phase 3 clinical trial of iSCIB1+ for patients with advanced melanoma, a step that ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
MicuRx Pharmaceuticals, Inc. (MicuRx), a clinical-stage biopharmaceutical company focused on developing novel anti-infective ...
GlobalData on MSN
FDA puts REGENXBIO gene therapy trials on hold after brain tumour
A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
Clinical Trials Arena on MSN
Boehringer Ingelheim’s kidney drug reduces proteinuria by 40% in Phase II trial
Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney Week ...
MedPage Today on MSN
FDA Halts Two Gene Therapy Trials After Child Develops Brain Tumor
Studies of Hunter and Hurler syndromes on hold ...
Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results